Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer

Abstract Background Lenvatinib, programmed cell death 1 (PD-1) antibodies, and gemcitabine and oxaliplatin (GEMOX) chemotherapy have shown significant antitumor activity as first-line therapy against biliary tract cancer. This study evaluated their efficacy and safety as non-first-line therapy in ad...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Yang Tan, Kai Liu, Chengpei Zhu, Shanshan Wang, Yunchao Wang, Jingnan Xue, Cong Ning, Nan Zhang, Jiashuo Chao, Longhao Zhang, Junyu Long, Xiaobo Yang, Daobing Zeng, Lijin Zhao, Haitao Zhao
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Springer 2024-10-01
Seri Bilgileri:	Cancer Immunology, Immunotherapy
Konular:	Gallbladder cancer Lenvatinib PD-1 GEMOX Chemotherapy Systemic therapy
Online Erişim:	https://doi.org/10.1007/s00262-024-03831-1
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!